Natural Compound Alnustone Reverses Fatty Liver Disease by Boosting Mitochondrial Fat Burning
Alnustone, from a traditional Chinese herb, targets calmodulin to enhance mitochondrial fatty acid oxidation and reverse liver steatosis in mice.
Summary
Researchers at Shandong University found that alnustone, a natural diarylheptanoid compound from the herb Alpinia katsumadai, potently reduces liver fat accumulation in multiple mouse models of MASLD and MASH. The compound works by directly binding calmodulin, a calcium-sensing protein, elevating cytosolic and mitochondrial calcium levels, and boosting mitochondrial fatty acid beta-oxidation. Treatment reduced serum and hepatic triglycerides, reversed liver steatosis, alleviated insulin resistance in both male and female mice, and ameliorated established liver fibrosis—without observable side effects. Calmodulin was found to be downregulated in human MASLD/MASH liver tissue and genetically associated with reduced MASLD risk, strengthening its relevance as a therapeutic target.
Detailed Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects roughly 30% of the global population and, in its more severe form MASH, can progress to cirrhosis, liver cancer, and liver failure. Only one FDA-approved drug (resmetirom) currently exists specifically for these conditions, creating an urgent need for new therapeutics. This study investigates alnustone—a diarylheptanoid natural product from the traditional Chinese herb Alpinia katsumadai—as a candidate treatment.
Using high-fat diet (HFD) mouse models, the researchers administered 10 mg/kg alnustone intraperitoneally daily for two weeks following 12 weeks of HFD feeding. Both male and female treated mice showed significantly reduced serum and hepatic triglycerides (liver TG down ~28%), decreased lipid droplet accumulation on H&E and Oil Red O staining, and improved glucose tolerance and insulin sensitivity. In a diet-induced MASH model with established liver fibrosis, alnustone also meaningfully reduced fibrosis markers without detectable toxicity.
To uncover the mechanism, the team performed hepatic lipidome profiling and energy metabolic assays, revealing that alnustone specifically enhances mitochondrial fatty acid beta-oxidation rather than suppressing lipid synthesis or altering fat export. Using limited proteolysis-mass spectrometry (LiP-SMap)—an unbiased thermal stability-based target identification approach—calmodulin was identified as a direct molecular binding target. Validation experiments confirmed alnustone binds the Ca2+-binding site of calmodulin, increasing both cytosolic and mitochondrial calcium levels and enhancing mitochondrial membrane potential and respiratory function.
Critically, liver-specific calmodulin knockdown using AAV-mediated shRNA completely abrogated alnustone's therapeutic effects, confirming calmodulin is the essential mediator. Supporting translational relevance, calmodulin expression was found to be downregulated in human liver biopsies from MASLD and MASH patients, and genetic analysis revealed calmodulin variants are associated with reduced MASLD risk in humans.
These findings position alnustone as a promising natural compound for MASLD/MASH therapy and identify calmodulin as a previously underappreciated but genetically validated therapeutic target in metabolic liver disease. The study is limited by reliance on mouse models and intraperitoneal delivery, and further pharmacokinetic and clinical studies are needed.
Key Findings
- Alnustone reduced hepatic triglycerides by ~28% in both male and female HFD-fed mice after 2 weeks.
- The compound directly binds calmodulin's Ca2+-binding site, raising mitochondrial Ca2+ and boosting fatty acid beta-oxidation.
- Liver-specific calmodulin knockdown completely abolished alnustone's anti-steatotic effects, confirming mechanistic specificity.
- Alnustone ameliorated established liver fibrosis in MASH mice without detectable side effects.
- Calmodulin is downregulated in human MASLD/MASH livers and genetically linked to reduced MASLD risk.
Methodology
Male and female C57BL/6 mice were fed a high-fat diet for 12 weeks to establish MASLD, then treated with alnustone (10 mg/kg IP daily) for 2 weeks. Mechanistic target identification used limited proteolysis-mass spectrometry (LiP-SMap); liver-specific calmodulin knockdown was achieved via AAV-delivered shRNA to confirm on-target activity.
Study Limitations
All efficacy data are from mouse models using intraperitoneal delivery, which may not translate directly to oral human dosing. Human genetic association data are correlational; clinical trials are needed to establish safety and efficacy in people. The study did not assess long-term toxicity or effects beyond 2–4 weeks of treatment.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.